This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox GGC2
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Cross-Linked B28 ASP Insulin== | ==Cross-Linked B28 ASP Insulin== | ||
<StructureSection load='1ZEI' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1ZEI' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| - | + | The monomeric, fast-acting hormone, mutant insulin B28 Pro --> Asp, has reduced the likely hood to form dimers and hexamers for therapeutic purposes. Around small phenolic derivatives mutant insulin B28 can create zinc hexamers, this is used as antimicrobial agents in insulin preparation. in the presence of phenol and m-cresol B28 Asp Insulin has been able to form crystals, containing aromatic side chains at the dimer-dimer interfaces and the monomer-monomer interfaces. However, at the monomer-monomer interfaces, there is a higher conformational flexibility in the B chains, caused by the B28 Pro --> Asp mutation. Additionally, this results in the loss of importance in the intermolecular force. It was discovered, that the binding of two m-cresol molecules disordered the beta- strand in a dimer. This indicated the cross link causes a strain on the B chain, which weakens the monomer-monomer interfaces. | |
| - | + | ||
== Function == | == Function == | ||
Revision as of 04:04, 23 April 2018
Cross-Linked B28 ASP Insulin
| |||||||||||
